Organovo Holdings, INC 8-K filings

VivoSim Labs announced it has regained compliance with Nasdaq's minimum stockholders equity requirement and anticipates over 500% revenue growth in fiscal year 2027.

VivoSim Labs, Inc. announced its 2026 Annual Meeting of Stockholders will be held on September 30, 2026, with a record date of August 13, 2026, and outlined deadlines for shareholder nominations and proposals.

VivoSim Labs received a notice from Nasdaq for failing to meet minimum stockholders equity requirements but has a plan to regain compliance, bolstered by recent transactions.

VivoSim Labs announced the pricing of a $4.0 million private placement of common stock and warrants to a single healthcare-focused institutional investor.

VivoSim Labs, Inc. announced the results of its 2025 Annual Meeting, where stockholders elected two Class II directors and approved executive compensation.

VivoSim Labs strengthens its leadership with the appointment of Tony Lialin as Chief Commercial Officer, aiming to scale its AI-enabled 3D human tissue toxicology services.

VivoSim Labs, Inc. has been notified by Nasdaq that it has regained compliance with minimum stock price and stockholders' equity requirements, avoiding delisting.

VivoSim Labs, Inc. (Nasdaq: VIVS) emerges from stealth mode to disrupt the drug discovery and development market with its new approach methodologies (NAM) models, capitalizing on the FDA's initiative to phase out animal testing.

Organovo Holdings, Inc. will rebrand as VivoSim Labs, Inc., effective April 24, 2025, and will trade under the new ticker symbol VIVS on the Nasdaq Capital Market.

Organovo reports preliminary cash balance of $11.3 million, net cash utilization of $2.0-$2.2 million for Q4 2025, and expects to meet Nasdaq continued listing requirements.

Organovo announces a business update, highlighting the successful sale of its FXR Program to Lilly and its plans to leverage replenished capital for future IBD opportunities.

Organovo Holdings, Inc. finalizes the sale of its FXR program to Eli Lilly and Company, receiving $10 million upfront and potential milestone payments.

Organovo Holdings implemented a 1-for-12 reverse stock split effective March 20, 2025, to meet Nasdaq's minimum bid price requirement.

Organovo Holdings, Inc. will implement a 1-for-12 reverse stock split effective March 20, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

Organovo Holdings, Inc. has issued an additional 2,967,144 shares of common stock through warrant exercises and at-the-market stock sales, expecting gross proceeds of approximately $2.3 million.

Organovo Holdings, Inc. will sell its FXR program, including lead asset FXR314, to Eli Lilly and Company for an upfront payment and potential milestone payments totaling up to $60 million.

Organovo Holdings, Inc. has received a notice from Nasdaq indicating that it has not regained compliance with the minimum bid price requirement and is facing potential delisting.

Organovo Holdings, Inc. has appointed Norman Staskey as its new President and Chief Financial Officer, effective December 30, 2024, following the resignation of Tomas Hess.

Organovo Holdings' shareholders approved an increase in shares for their equity incentive plan and authorized a reverse stock split at the 2024 Annual Meeting.

Organovo Holdings granted time-based and performance-based stock options to its Executive Chairman, Keith Murphy, on August 5, 2024.

Organovo Holdings has received a notice from Nasdaq for failing to maintain a minimum share price of $1, potentially leading to delisting if compliance is not regained by January 14, 2025.

Organovo Holdings, Inc. has announced the pricing of a public offering to raise $5.25 million through the sale of common stock and warrants.

Organovo is advancing its lead drug candidate, FXR314, for inflammatory bowel disease and liver conditions, with Phase 2a results expected in the second half of 2025.

Organovo Holdings has raised approximately $1.8 million through an at-the-market offering by issuing 1,349,778 shares of common stock between February 1, 2024 and April 19, 2024.

Organovo's FXR agonist, FXR314, demonstrated positive results in 3D models of Crohn's disease and ulcerative colitis, showing potential for treating inflammatory bowel diseases.